A4GNT抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07722(A4GNT Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07722(A4GNT Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The A4GNT antibody targets the α1.4-N-acetylglucosaminyltransferase (A4GNT) enzyme, a glycosyltransferase critical for synthesizing unique O-glycan structures in the gastrointestinal tract. A4GNT catalyzes the transfer of GlcNAc residues via α1.4-linkages to core 1 mucin-type O-glycans, forming terminal α1.4-GlcNAc-capped structures. These glycans are predominantly expressed in gastric gland mucous cells and play a key role in mucosal defense.

A4GNT's activity is particularly associated with the formation of the "glycoform" recognized by the pathogen Helicobacter pylori, which binds to α1.4-GlcNAc residues during gastric colonization. Reduced A4GNT expression has been linked to gastric pathologies, including chronic gastritis and gastric cancer, as impaired α1.4-GlcNAc production compromises mucosal barrier function. A4GNT antibodies are valuable tools for studying mucin glycosylation patterns, host-pathogen interactions, and gastric disease mechanisms. They enable detection of A4GNT protein localization in tissues, assessment of enzyme expression levels, and functional studies exploring glycosylation's role in mucosal homeostasis. Recent research also investigates A4GNT's potential as a biomarker for early gastric cancer detection and its involvement in intestinal metaplasia progression.